A 62-year-old man with a 5-year history of Parkinson disease is being evaluated for motor complications. Which clinical feature best distinguishes idiopathic Parkinson disease from atypical parkinsonian syndromes (progressive supranuclear palsy and multiple system atrophy)?

Explanation

## Distinguishing Idiopathic Parkinson Disease from Atypical Parkinsonian Syndromes ### Key Discriminating Features **Key Point:** Preserved vertical gaze and delayed postural instability are hallmark features of idiopathic Parkinson disease (IPD) and help distinguish it from atypical parkinsonian syndromes (APS). ### Comparative Table | Feature | Idiopathic PD | Progressive Supranuclear Palsy (PSP) | Multiple System Atrophy (MSA) | |---------|---------------|--------------------------------------|-------------------------------| | **Vertical gaze** | Preserved (early) | Impaired early (supranuclear) | Preserved | | **Postural instability** | Late feature (>3 yrs) | Early feature (<1 yr) | Early feature (<2 yrs) | | **Autonomic dysfunction** | Late/mild | Mild | Prominent early | | **Cerebellar signs** | Absent | Absent | Present (MSA-C) | | **Dementia** | Later stage | Early (cognitive decline) | Variable | | **L-DOPA response** | Excellent (early) | Poor | Poor/minimal | | **Progression rate** | Slow (10+ yrs) | Rapid (5–8 yrs) | Rapid (5–10 yrs) | **High-Yield:** Vertical supranuclear gaze palsy (especially downward gaze impairment) is the **signature finding of PSP** and is virtually absent in early IPD. Early postural instability (within 1 year) is a **red flag for APS**, not IPD. ### Clinical Pearl **Clinical Pearl:** The "**Red Flags for Atypical Parkinsonism**" mnemonic is SARA: - **S**upranuclear gaze palsy (PSP) - **A**utonomic dysfunction early (MSA) - **R**apid progression (APS generally) - **A**symmetric features less prominent (APS tend to be more symmetric) IPD typically presents with **asymmetric onset**, preserved vertical gaze, and **excellent response to levodopa** in early stages. ### Why This Distinction Matters 1. **Prognosis:** IPD has slower progression; APS progress rapidly and have poorer outcomes. 2. **Treatment:** IPD responds to dopaminergic agents; APS do not. 3. **Pathology:** IPD = Lewy bodies; APS = tau/α-synuclein inclusions in different distributions. [cite:Harrison 21e Ch 430]